Cervical cancer remains a major global health challenge, particularly in advanced stages where prognosis is poor despite recent therapeutic advances. The immunological landscape of cervical cancer offers a rationale for strategies aimed at enhancing tumor-specific immune responses. Based on this rational, several clinical trials have led to approval of immune checkpoint inhibitors for the treatment of Locally Advanced Cervical Cancer (CC) and Recurrent/Metastatic disease. The incorporation of Immune Checkpoint Inhibitors such as pembrolizumab and cemiplimab in the CC treatment has led to significant improvements in survival. However, primary and acquired resistance limits long-term efficacy, especially in patients with low PD-L1 expression or immunologically "cold" tumors. This review explores emerging immunotherapeutic approaches designed to overcome resistance, including novel checkpoint targets, tumor microenvironment modulation, therapeutic cancer vaccines, and adoptive cell therapies in cervical cancer. Early clinical data suggest that the combinations of these modalities may increase the proportion of patients who benefit from immunotherapy. Together, these strategies represent a dynamic immuno-oncology landscape with the potential to redefine treatment paradigms in cervical cancer. Ongoing clinical trials and translational studies will be key to identifying optimal combinations, timing, and patient populations most likely to derive durable benefit from these new interventions.
Yarza et al. (Fri,) studied this question.